Business Context and Reporting Period
This Form 8-K Current Report was filed by iBio, Inc. on October 7, 2022. The filing reports on a material corporate action involving a reverse stock split of the Company's common stock, effective as of October 7, 2022.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the structural change to the Company's capitalization.
Material Changes
- Reverse Stock Split: The Board of Directors approved a 1-for-25 reverse stock split. This was effected by filing a Certificate of Amendment with the Delaware Secretary of State on October 7, 2022.
- Share Count Reduction: The number of outstanding common shares was reduced from 225,164,563 to 9,006,583 shares.
- Trading Details: Post-split trading began on October 10, 2022, on the NYSE American under the symbol "IBIO" with a new CUSIP number (451033609).
- Fractional Shares: No fractional shares were issued. Holders entitled to fractional shares received cash in lieu thereof, calculated based on the average closing price over the ten trading days preceding the effective date.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard implications of a reverse stock split. The primary contingency noted is the cash payment mechanism for fractional shares, which could eliminate holders of 24 or fewer pre-split shares.
Investor Verification Checklist
- Verify the new CUSIP number (451033609) for future trading and record-keeping.
- Confirm the cash settlement amount for any fractional shares held prior to the split.
- Review the adjusted share count (9,006,583) for accurate ownership percentage calculations.
- Monitor the stock price on the NYSE American starting October 10, 2022, to ensure it reflects the post-split basis.